What Mucinex does

Mucinex is an over-the-counter consumer health brand specializing in cold, flu, sinus, and chest congestion relief, founded in 2003 and operated by RB Health (US) LLC, a subsidiary of UK-listed Reckitt. The brand is headquartered in Parsippany, New Jersey, and serves general adult consumers, children, healthcare providers, and (since late 2025) Canadian consumers. The product portfolio spans extended-release bi-layer tablets containing guaifenesin (and dextromethorphan/phenylephrine variants in the DM and D lines), Fast-Max liquid gels and caplets for multi-symptom cold/flu relief, Sinus-Max nasal sprays with proprietary POWER-JET and GENTLE-MIST 2-in-1 nozzle technologies, Nightshift formulations for nighttime symptom relief, Rapid Clear caplets, and pediatric formulations under the Children's line, plus the recently launched Clear & Cool Saline Nasal Spray.

Mucinex's core technological differentiator is its extended-release bi-layer tablet platform, which delivers 12 hours of symptom relief per dose, roughly double the dosing interval of most generic competitors. The brand also maintains a significant clinical evidence base, including long-term findings from the GASP Study demonstrating efficacy of extended-release guaifenesin over 12 weeks in patients with stable chronic bronchitis. The brand has been supported for over two decades by the distinctive Mr. Mucus mascot, which functions as the principal intangible asset underpinning consumer recognition.

The business model is a classic OTC consumer health model: one-time retail purchases through mass retail distribution (pharmacies, grocery, mass merchants) in the US and Canada, supplemented by direct-to-consumer e-commerce via mucinex.com. Products are HSA/FSA eligible. The brand does not disclose its revenue separately; financial results are consolidated within Reckitt's Health segment. Marketing relies on a multi-channel approach including social media (Facebook, Instagram, YouTube), content marketing via a Tips & Resources learning center, public relations, and high-visibility experiential campaigns (e.g., the 2025 AR-enhanced 3D art installation at Grand Central Terminal with artist Kurt Wenner).

Name

Mucinex

Legal name

RB Health (US) LLC

Website

https://mucinex.com

Company type

Private

Founded year

2003

Operating status

Operating

Headcount range

11–50 employees

Short description

Mucinex is a US OTC consumer health brand owned by Reckitt, providing 12-hour extended-release cold, flu, sinus, and chest congestion relief products for general adults, children, and now Canadian consumers, distributed through major retailers and direct e-commerce.

Ownership category

akta.pro rank

Product category

OTC Cold, Flu & Sinus Medications

NAICS

Soap and Cleaning Compound Manufacturing (32561)

akta.pro primary industry

Cold, Flu, Cough & Allergy Remedies (Decongestants, Antihistamines, Cough Syrups, Lozenges) (CRADAMAD)

akta.pro secondary industries

Cold, Flu & Cough Remedies (HLAIADAB), Pediatric OTC Medicines (HLAIADAL), Nasal Drug Delivery Devices (Sprays/Powder Devices) (HLAHAIAK)

Keywords

• OTC cold and flu remedies
• Extended-release expectorant tablets
• Nasal decongestant sprays
• Pediatric cough medications
• Sore throat relief products

Headquarters

HQ city

New York

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2C

Offering type

Hardware or Manufacturing

Cost components

Operations, Marketing or Sales, Supply Chain, Technology or R&D, Personnel

Revenue model

1. OTC Pharmaceutical Products: Mucinex generates revenue through the sale of over-the-counter cold, flu, and sinus relief medications including extended-release tablets, liquid gels, caplets, and nasal sprays. Products are sold as one-time purchases through retail partners and direct-to-consumer e-commerce channels. HSA/FSA eligible expenses.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels5 records

Core offering

Mucinex manufactures and sells over-the-counter cold, flu, sinus, cough, and sore throat medications for adults and children under the Mucinex brand umbrella. Its core technology is a 12-hour extended-release bi-layer tablet (guaifenesin-based), complemented by fast-acting liquid gels, caplets, nasal sprays with POWER-JET and GENTLE-MIST nozzle systems, and pediatric formulations. Products are sold as one-time purchases in retail stores and direct-to-consumer e-commerce.

Product overview

Mucinex is an over-the-counter (OTC) cold, flu, and sinus relief brand owned by Reckitt. The product portfolio is structured as a multi-format platform approach, offering medications in extended-release bi-layer tablets, fast-acting liquid gels/caplets, nasal sprays, and children's formulations. The core products include Mucinex Extended-Release Bi-Layer Tablets (the original guaifenesin-based chest congestion product), the Fast-Max line (liquids and caplets for multi-symptom cold and flu), Sinus-Max products (targeting sinus and nasal congestion including Clear & Cool nasal sprays), Nightshift formulations (specialized nighttime products for sleep-friendly symptom relief), Rapid Clear (rapid-release caplets), and children's variants. The products work together as a comprehensive symptom management system covering cough, chest congestion, sinus/nasal congestion, cold, flu, sore throat, and pain symptoms across different age groups and symptom severities.

Differentiator

Problem solved

Functional benefit

Brands

• Fast-Max: Line of fast-acting liquid and gel cold and flu relief products
• Sinus-Max
• Nightshift
• InstaSoothe
• Rapid Clear
• Children's Products

Products and services

• Mucinex Extended-Release Bi-Layer Tablets Extended-release bi-layer tablets containing guaifenesin for chest congestion relief. Provides 12-hour symptom relief by thinning and loosening mucus in the airways. Targeted at adults with chest congestion.
• Mucinex DM Extended-Release Bi-Layer Tablets Extended-release bi-layer tablets combining guaifenesin (expectorant) and dextromethorphan (cough suppressant) for chest congestion and cough relief over 12 hours. Targeted at adults with cough and chest congestion.
• Maximum Strength Mucinex DM Extended-Release Bi-Layer Tablets Maximum strength version of extended-release bi-layer tablets combining guaifenesin and dextromethorphan for severe chest congestion and cough, providing 12-hour relief. Targeted at adults with severe cough and congestion.
• Mucinex Fast-Max Liquid Products Fast-acting liquid and liquid gel formulations for multi-symptom cold and flu relief. Includes Day and Night formulas, severe cold variants, and combination packs. Targeted at adults needing multi-symptom cold and flu relief.
• Mucinex Fast-Max Caplets Rapid-release caplet formulations for cold, flu, and congestion symptoms. Includes Day Cold & Flu, Night Cold & Flu, Severe Congestion & Cough, and Cold, Flu & Sore Throat variants. Targeted at adults with multi-symptom cold and flu.
• Mucinex Sinus-Max Products Product line specifically targeting sinus symptoms including nasal sprays, liquid gels, caplets, and combination day/night packs. Includes Clear & Cool nasal spray with menthol cooling sensation. Targeted at adults with sinus and nasal congestion.
• Sinus-Max Severe Nasal Congestion Relief Clear & Cool Nasal decongestant spray with oxymetazoline hydrochloride (0.05%) providing up to 12 hours of relief with a cooling menthol flavor. Fast-acting for day and night use. Targeted at adults with severe nasal congestion.
• Mucinex Sinus-Max Saline Nasal Spray Drug-free saline nasal spray with 2-in-1 nozzle technology featuring POWER-JET for tough congestion (ages 6+) and GENTLE-MIST for everyday use (ages 2+). Targeted at adults and children with everyday nasal congestion.
• Mucinex Sinus Clear & Cool Saline Nasal Spray Saline nasal spray with instant cooling sensation for congestion relief. Features dual spray settings — POWER-JET for tough congestion (ages 12+) and GENTLE-MIST for everyday use. Targeted at adults and older children with congestion seeking drug-free relief.
• Mucinex Nightshift Products Nighttime-specific formulations for cold, flu, and sinus symptoms. Includes Nightshift Cold & Flu (liquid and caplets), Nightshift Sinus, and Nightshift Severe Cold & Flu variants. Designed to help users sleep and wake up feeling better. Targeted at adults whose symptoms disrupt sleep.
• Mucinex Rapid Clear Products Rapid-release caplet line for fast symptom relief. Includes DayTime (Pain, Headache & Mucus Congestion) and NightTime (Headache, Cough & Fever) formulations, plus combination packs. Targeted at adults needing fast-acting relief.
• Mucinex Children's Products Product line formulated for children including liquids, mini-melts, chewable tablets, and multi-symptom cold & flu formulations. Available in flavors such as Very Berry, Cherry, Mixed Berry, and Orange Creme. Targeted at parents/caregivers treating pediatric cough, congestion, and cold symptoms.
• Mucinex InstaSoothe Products Sore throat relief line including Kickstart Sore Throat Spray (Winterfresh flavor), Sore Throat + Cough Relief, Sore Throat + Pain Relief (drops and spray), Soothing Comfort, and Sugar-Free Cough Drops (Mixed Berry). Targeted at adults with sore throat and cough symptoms.

Quantifiable outcome

• 12-hour symptom relief duration from extended-release formulations
• +2 more outcomes

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

One partnership is on record.

• Kurt WennerminorStrategic or Co-development Partner · 1 December 2025Mucinex partnered with artist Kurt Wenner to create an experiential 3D art exhibit at Grand Central Terminal (December 1-7, 2025). The glacier-inspired installation promoted the new Clear & Cool Sinus Nasal Spray with interactive AR elements, visually representing the product's cooling relief benefit.

Scale indicators1 record

Recent moves6 records

Expansion highlights5 records

Direct peers

• Robitussin: Robitussin (Haleon) is a direct OTC competitor offering cough, chest congestion, and multi-symptom cold/flu products (including DM formulations) targeting the same adult self-medication occasions as Mucinex's DM and Maximum Strength SKUs.
• Tylenol Cold & Flu: Tylenol Cold & Flu (Kenvue / Johnson & Johnson) is a direct competitor in cold/flu multi-symptom relief, anchored by acetaminophen-based formulations. Tylenol's household-name brand and similar SKU structure make it one of Mucinex's closest OTC rivals on shelf.
• Alka-Seltzer Plus: Alka-Seltzer Plus (Bayer) is a direct competitor offering effervescent and cold/flu multi-symptom formulations, addressing the same self-medication use cases and competing for the same cold/flu shelf space as Mucinex's Fast-Max line.
• Sudafed: Sudafed (Kenvue) competes directly with Mucinex's Sinus-Max decongestant and pressure/pain SKUs in the nasal and sinus congestion category, using pseudoephedrine/phenylephrine-based formulations targeting the same adult consumer.
• DayQuil / NyQuil: DayQuil and NyQuil (Procter & Gamble / Vicks franchise) are direct day/night multi-symptom cold and flu competitors. They share the same shelf positioning, retail channels, and adult consumer occasions as Mucinex's Fast-Max and Nightshift product lines.
• Theraflu: Theraflu (Haleon) targets multi-symptom cold and flu relief through powdered and liquid formulations, directly competing with Mucinex Fast-Max in the same adult self-medication segment and same retail OTC shelves.
• Vicks: Vicks (Procter & Gamble) competes across cough, cold, and sinus categories with VapoRub, NyQuil/DayQuil, and Sinex nasal sprays — overlapping Mucinex's chest congestion, multi-symptom, and sinus nasal spray lines with similar retail placement.

Emerging players

• Benadryl: Benadryl (Kenvue) competes in adjacent OTC allergy/sinus categories that overlap with Mucinex's Sinus-Max line and overlap consumer occasions for multi-symptom relief, though Benadryl's core franchise is antihistamine-driven rather than expectorant.

Broad incumbents

• Kenvue: Kenvue (spun out of Johnson & Johnson) owns Tylenol, Sudafed, Benadryl, Zyrtec, and Nicorette — a portfolio that directly overlaps Mucinex's cold/flu/sinus/allergy categories and competes for the same shelf, retailer relationships, and consumer occasions at global scale.
• Haleon: Haleon is a global consumer health platform that owns Robitussin, Theraflu, Advil, Centrum, and Sensodyne, giving it broad OTC reach that includes direct Mucinex competitors. As Reckitt's closest peer in consumer health scale, Haleon represents the strategic benchmark for portfolio breadth and international reach.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/channel/UCJ_go6CYYTBSSEnmvYpYe1g/featured
• Facebookfacebook.com/mucinex
• Instagraminstagram.com/mucinex_us?hl=en
• Xx.com/mucinex

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Mucinex